Display options
Cite
D'Silva KM, Serling-Boyd N, Wallwork R, et al. Response to: 'COVID-19 in patients with rheumatic diseases: what is the real mortality risk?' by Marques . Ann Rheum Dis. 2020;doi: 10.1136/annrheumdis-2020-218431.
D'Silva, K. M., Serling-Boyd, N., Wallwork, R., Hsu, T. Y., Sparks, J. A., & Wallace, Z. S. (2020). Response to: 'COVID-19 in patients with rheumatic diseases: what is the real mortality risk?' by Marques . Annals of the rheumatic diseases, . https://doi.org/10.1136/annrheumdis-2020-218431
D'Silva, Kristin M, et al. "Response to: 'COVID-19 in patients with rheumatic diseases: what is the real mortality risk?' by Marques ." Annals of the rheumatic diseases vol. (2020). doi: https://doi.org/10.1136/annrheumdis-2020-218431
D'Silva KM, Serling-Boyd N, Wallwork R, Hsu TY, Sparks JA, Wallace ZS. Response to: 'COVID-19 in patients with rheumatic diseases: what is the real mortality risk?' by Marques . Ann Rheum Dis. 2020 Jul 13; doi: 10.1136/annrheumdis-2020-218431. Epub 2020 Jul 13. PMID: 32660976.
Copy Download .nbib Format: NLM
Share it on

Ann Rheum Dis. 2020 Jul 13; doi: 10.1136/annrheumdis-2020-218431. Epub 2020 Jul 13.

Response to: 'COVID-19 in patients with rheumatic diseases: what is the real mortality risk?' by Marques .

Annals of the rheumatic diseases

Kristin M D'Silva, Naomi Serling-Boyd, Rachel Wallwork, Tiffany Y-T Hsu, Jeffrey A Sparks, Zachary Scott Wallace

Affiliations

  1. Division of Rheumatology, Allergy, and Immunology, Harvard Medical School, Boston, Massachusetts, USA.
  2. Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  3. Division of Rheumatology, Allergy, and Immunology, Harvard Medical School, Boston, Massachusetts, USA [email protected].

PMID: 32660976 DOI: 10.1136/annrheumdis-2020-218431

[No abstract available.]

Keywords: antirheumatic agents; arthritis, rheumatoid; epidemiology; health services research

Publication Types